Company Encyclopedia
View More
name
Nanosonics Limited
NAN.AU
News
View More

Nanosonics Limited Announces Hybrid 2025 AGM to Boost Shareholder Engagement

Nanosonics Limited (AU:NAN) has announced its 2025 Annual General Meeting (AGM) will be a hybrid event, allowing shareholders to participate in person or online. This initiative aims to enhance accessibility and engagement, enabling real-time questions and voting. The latest analyst rating for AU:NAN is a Buy with a price target of A$4.90. Nanosonics specializes in infection prevention solutions in healthcare, particularly ultrasound probe disinfection, with a current market cap of A$1.31B and an average trading volume of 768,532.

Tip Ranks·
Tip Ranks·

Nanosonics Limited: Strong Defensive Position and Growth Potential with Trophon and CORIS

Nanosonics Limited is positioned strongly with its Trophon franchise, enhancing margins and supporting the upcoming CORIS product aimed at infection control. Despite market underestimation, CORIS's advanced cleaning capabilities and the need for investment in clinical efficacy are noted. The Trophon franchise has diversified revenue streams, stabilizing earnings amid competition. Growth is seen in EMEA, Japan, and China through third-party distribution. Recent FDA approval of CORIS highlights its efficacy, but market access requires integration into clinical guidelines. Analyst Davinthra Thillainathan maintains a positive outlook with a Buy rating and A$4.50 price target.

Tip Ranks·
Tip Ranks·

Nanosonics Director Adjusts Equity Holdings

Nanosonics Limited (AU:NAN) announced a change in director Michael Kavanagh's equity holdings, acquiring 109,685 ordinary shares through the Omnibus Equity Plan. This adjustment aims to align management interests with shareholder value, potentially influencing investor confidence. The latest analyst rating for AU:NAN is a Buy with a price target of A$4.50. Nanosonics specializes in medical technology, particularly infection prevention solutions, and has a current market cap of A$1.25B.

Tip Ranks·
Tip Ranks·

Nanosonics Limited Issues New Securities Under Employee Incentive Scheme

Nanosonics Limited (AU:NAN) has announced the issuance of 289,148 ordinary fully paid securities under an employee incentive scheme, which will be quoted on the ASX. This initiative reflects the company's commitment to employee retention and market strength. The latest analyst rating for AU:NAN is a Buy with a price target of A$4.50. Nanosonics specializes in infection prevention solutions in the healthcare sector, particularly in ultrasound probe disinfection, with a current market cap of A$1.25B.

Tip Ranks·
Tip Ranks·

Nanosonics Limited Releases 2025 Annual Report Highlighting Sustainability and Product Updates

Nanosonics Limited has released its 2025 Annual Report, emphasizing sustainability and product updates, including trophon®2 and CORIS®. The report outlines the company's financial and operational performance, strategic direction, and future growth prospects, which are crucial for stakeholders. The latest analyst rating for Nanosonics (AU:NAN) is a Buy with a price target of A$5.15. The company has a market cap of A$1.23B and a year-to-date price performance of 34.55%.

Tip Ranks·
Tip Ranks·